A multi-site, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of trehalose-reformulated peru-15 (Choleragarde)vaccine [cholera vaccine live attenuated] given simultaneously with measles vaccine [measles virus vaccine live] in healthy Indian and Bangladeshi infants.

Trial Profile

A multi-site, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of trehalose-reformulated peru-15 (Choleragarde)vaccine [cholera vaccine live attenuated] given simultaneously with measles vaccine [measles virus vaccine live] in healthy Indian and Bangladeshi infants.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2014

At a glance

  • Drugs Cholera vaccine live attenuated; Measles virus vaccine live
  • Indications Cholera; Measles; Vibrio infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 31 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Mar 2012 Planned end date changed from 1 May 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top